CAG inhibits glucose reabsorption in ZDF rats
Inhibiting
glucose reabsorption in kidney and promoting glucose efflux out are
using therapeutic approaches for diabetes in clinic. After the treatment
of Dapagliflozin or CAG for one week, we tested the level of
urinary glucose and sodium, and urine efflux volume in ZDF mice at
different time points in 24 hours. Dapagliflozin significantly increased
the urinary glucose and sodium in each period within a day, while showed
nearly no effect on urine efflux volume (Figure 6A-6C). Similar to
Dapagliflozin, CAG increased urinary glucose, urinary sodium
but a marginally decrease in the urinary efflux volume (Figure 6A-6C).
Similar results appeared in ZDF rats whose administration was extended
to 5 weeks (Figure 6D-6F). Of note, after 5-week administration, bothCAG and Dapagliflozin decreased the water intake volume (Figure
6G), suggesting the inhibitory effects on glucose reabsorption and the
promotion of glucose efflux out.